top of page
​BioFinland Member

BioFinland Member

RNatives Oy

RNatives Oy
Company name

RNatives Oy


Microkatu 1 R, FI-70210 Kuopio







Contact person

Mikko Turunen


Juhani Lahdenperä

Main categories

Drug Discovery and Development / Drug Delivery

Last updated

1 February 2023

Company profile

RNatives, Inc. is a US-based RNA activation (saRNA) therapeutics platform company and RNatives Oy is it's subsidiary operating R&D unit in Kuopio. The RNA activation (saRNA) platform enables the modulation of a target gene expression in target cells by nuclear microRNA (miRNA) biology. The new miRNA biology was discovered by our Founder, Mikko Turunen, and his research group after years of basic research work. The Company's lead program is focusing on Heart Failure (HF) and Peripheral Artery Disease (PAD). The technology upregulates Vascular Endothelial Growth Factor A (VEGFA) expression in the affected tissue by novel miRNA for driving the new blood vessel formation and recovery from the disease condition. Company also has in development miRNA drug for the treatment diseases of CNS. RNatives is also developing engineered exosomes for the delivery of RNA drugs.

bottom of page